timothy sykes logo
Hims & Hers Faces Investigation Amid Wegovy Sales Discontinuation Thumbnail
ADD US ONG Google News

Hims & Hers Faces Investigation Amid Wegovy Sales Discontinuation

ELLIS HOBBS•UPDATED MAR. 12, 2026, 2:33 PM ET
Reviewed by Matt Monaco Fact-checked by Bryce Tuohey

Hims & Hers Health Inc. stocks have been trading down by -4.95 percent amid concerns over business model viability.

  • Post-investigation news, stock value saw a drop due to potential regulatory scrutiny and product technology concerns.

  • Questions arose about the firm’s weight-loss product following a critical New York Times report, casting doubts on clinical trial backing.

  • An ongoing investigation explores securities law violations tied to GLP-1 APIs as Novo Nordisk’s lawsuit looms.

  • Investor confidence remains shaky after mixed revenue guidance and strategic challenges questioning company’s trajectory.

Candlestick Chart

Live Update At 14:32:59 EDT: On Thursday, March 12, 2026 Hims & Hers Health Inc. stock [NYSE: HIMS] is trending down by -4.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Hims & Hers finds itself navigating turbulent waters lately. Their decision to halt the sale of its version of Wegovy followed a report questioning the technology and lack of clinical trials, sparking legal scrutiny. The revenue guidance for Q1 was marked at $600M–$625M, a notable miss compared to the expected $652.59M, raising eyebrows. Adjusted EBITDA projections too seem conservative, pegged between $35M and $55M.

Stock charts narrate a story of volatility. Over the past weeks, prices tumbled from recent highs of $27.24 to closing around $24.565, reflecting market hesitations. Financial ratios shed some light – with a gross margin at 73.8%, showing effective cost control. Yet, challenges remain with a price-to-sales ratio of 2.28 amidst a lofty P/E ratio of 46.94.

Profit margins remain modest yet stable, underscoring sustained sales performance. Concerns about Hims & Hers’ ability to maintain growth are valid, given debt obligations with a total debt-to-equity ratio of 2.07. High leverage poses risks in these uncertain times.

The company’s focus on marketing, comprising a substantial portion of operating expenses, targets expanding consumer engagement. However, skepticism exists around sustaining aggressive growth targets, especially as the Wegovy debacle shadows strategic prospects. Financially, despite robust foundations, adaptability will be vital for long-term endurance. Investors are likely to keep a close eye on legal proceedings as they unfold.

Legal Probe and Market Sentiment

The discontinuation of Wegovy, amid legal investigations into possible fiduciary failures, rattles the company’s stability, overshadowing recent financial guidance shortfalls. Allegations follow a news exposé igniting concerns over unproven product claims, shaking investor faith and dampening the stock’s appeal.

In public markets, this translates to heightened volatility in shares as JP Morgan trimming its stake reinforces a general air of caution. Investor sentiment, sensitive to media narratives, could see fluctuations as the investigation resolves or evolves. Hims & Hers, holding strong in some metrics and softer in others, faces a perceptual uphill battle that could dictate market conditions ahead.

More Breaking News

Conclusion

Hims & Hers Health finds itself on the defensive, contending with legal inquiries and financial guidance recalibrations. The combination of regulatory vigilance and potential product setbacks paints a complex operational picture. Traders must watch for developments closely — the unfolding legal situations paired with market reactions could significantly tilt strategic decisions and stock trajectory in the coming quarters. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This mindset is crucial for traders observing Hims & Hers Health to avoid unnecessary risks and losses. Adaptability to forecasted challenges, reinforced by proactive management of legal risks, will be imperative to regain momentum and restore confidence within Hims & Hers Health’s stakeholder framework.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading HIMS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”